SPI Infoamtion

Table of Contents

Executive summary

Defining nutrigenomics
Market drivers
Collaborative nutrigenomic research & consortia
Leading food & drinks companies: nutrigenomic strategies
Leading nutrigenomic testing companies
Opportunities: convergence of pharma & diagnostics
Challenges: regulation, ethical & IP issues
Conclusions

Chapter 1 Defining nutrigenomics

Summary
Introduction
‘Omic technologies
Nutrigenomics and the food & drinks industry
Nutrigenomics & food products
Nutrigenomics & personalized nutrition
Report outline

Chapter 2 Market drivers

Summary
Introduction
Drivers for personalized nutrition

Healthy aging
Consumer demographics
Chronic non-communicable disease
Urbanization and the emerging markets
Global health economics
Conclusions on drivers for personalized nutrition

Chapter 3 Collaborative nutrigenomic research & consortia

Summary
Introduction
Nutrigenomic research consortia

Nutrigenomic research in the EU
The European Nutrigenomics Organization (NuGO)
DiOGenes
TI Food and Nutrition
Vision EpiFood Project
Canada Foundation for Innovation (CFI)
Public-private in age-related diseases
Nutrigenomic research in the US
Public-private partnership: genetically modified crops
Nutrigenomic research across the world
International Society of Nutrigenetics/Nutrigenomics (ISNN)

Conclusions

Chapter 4 Leading food & drinks companies: nutrigenomic strategies

Summary
Introduction
Ingredients manufacturers approach to nutrigenomics

BASF
Chr Hansen
DSM

Food manufacturers’ approach to nutrigenomics

Group Danone
Nestle
Unilever

Pharma industry M&A in consumer nutrition
The evolving open network model
Co-development opportunities
Areas for market growth & time scales
Conclusions

Chapter 5 Leading nutrigenomic testing companies

Summary
Introduction
Market leaders

23andme.com
GeneLink
Gene Smart
Genova Diagnostics
Interleukin Genetics Inc
WellGen Inc.

Conclusions

Chapter 6 Opportunities: convergence of pharma & diagnostics

Summary
Introduction
Nutrigenomics vs pharmacogenomics
Global health issues treatment vs prevention
Convergence of the pharmaceutical & diagnostic market
Conclusions

Chapter 7 Challenges: regulation, ethical & IP issues

Summary
Introduction

Regulation of nutrigenomic foods
Europe
Japan
Regulation of nutrigenomic tests
Ethical issues
Public awareness & perceptions
Intellectual Property

Conclusions

Chapter 8 Conclusions

Summary
The food & drinks market
Global genetic testing market
Market trends
Overall conclusions

Appendix

Primary research methodology
Acknowledgments
Glossary
Index
Bibliography
Endnotes

List of Figures
Figure 1.1: Nutrigenetics and nutrigenomics
Figure 1.2: The ‘omics technologies
Figure 1.3: The functional genomic tool box
Figure 1.4: Applications of nutrigenomics in the food chain
Figure 2.5: Drivers for the food & drinks industry
Figure 2.6: The ageing population a driver for personalized nutrition
Figure 2.7: Personalized nutrition targeting consumer segments
Figure 2.8: Population over 60: world and developed regions (1950-2050)
Figure 2.9: Nutritional challenges . obesity & metabolic syndrome
Figure 2.10: Growth in consumers in developing & emerging countries (2008-2018)
Figure 2.11: Healthcare expenditure as a share of GDP (2006)
Figure 2.12: Target population of nutrigenomic based products
Figure 4.13: BASF approach to gene discovery
Figure 4.14: DSMs sales growth targeting four emerging business areas
Figure 4.15 DSMs R&D competencies
Figure 4.16 An International and interdisciplinary network
Figure 4.17 Diversify & de-risk through externalization
Figure 4.18 Open network model
Figure 4.19: Waves of nutrigenomic development
Figure 5.20: WellGen’s nutrigenomic based discovery
Figure 6.21: Nutrigenomics vs pharmacogenomics
Figure 6.22: Relationship of drugs, disease, genes and gene products
Figure 8.23: Health and nutrition market segments (2009)
Figure 8.24: Nutrigenomic impact on personalized nutrition

List of Tables
Table 3.1: European Consortia and Nutrigenomic Research Programs
Table 3.2: Nutrigenomics Network Programs
Table 4.3: Stakeholders in nutrigenomic research and personalized nutrition
Table 4.4: Chr Hansen - strategic alliances & investments
Table 4.5: Nestle nutrigenomic alliances & investments
Table 4.6: Divestment of Animal, Consumer & Medical Nutrition Divisions
Table 4.7: Consumer Health Divisions of Pharmaceutical Companies
Table 4.8: Alliance between Food, Pharma, Biotech and the Diagnostic Industries
Table 5.9: Categorization of genetic variations that may be included in nutrigenomic tests
Table 5.10: Categorization of genetic variations that may be included in nutrigenomic tests
Table 6.11: Known diet- gene interactions
Table 6.12: Known gene-nutrient interactions